Entera Bio Ltd.

NASDAQ:ENTX

Biotechnology

Healthcare
$3.26 +0.00%

+$0.00 today

Market cap
$567.69M
Beta
1.49
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.91High $3.22

Volume 0.49M

Average 0.16M

ENTX Other Non-current Assets

Long-term assets not reported separately.

Entera Bio Ltd.NASDAQ: ENTX

Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026

Other non-current assets rises 1500.0% from a year ago

Other non-current assets stood at $96K at the end of Q1 FY2026, up 1500.0% from a year earlier and up 206.7% from the prior quarter.

Context

  • Other non-current assets amounted to 0.7% of total assets at the end of Q1 FY2026, up 0.7 pp from a year earlier.
  • Other non-current assets increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether other non-current assets keeps rising in the next quarterly balance sheet after a +1500.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$96K+206.7% QoQ
Last fiscal yearDec 2025
-$90K-1600.0% YoY
Year agoMar 2025
$6K+1500.0% since
Other Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1500.0%——
1 year-1600.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-current Assets history

USD · from the balance sheet

Latest · FY2025
(90K) USD
Year-over-year change
-1600.0%

Other Non-current Assets vs competitors

How ENTX compares with its peers on the latest reported figures

  • ENTX's Mar 2026 other non-current assets of $96K is the 5th highest of the 10 companies compared; the peer median is $83K.
  • Its year-over-year change of +1500.0% is the highest of 7, against a peer median of -19.8%.
  • Other non-current assets amounts to 0.7% of total assets for ENTX, versus a peer median of 0.1%.
ENTX Competitors Peer median
Other Non-current Assets for ENTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SEERSeer, Inc.Mar 2026$4.32M -39.6%+49.6%1.6%
INOInovio Pharmaceuticals, Inc.Mar 2026$2.01M +1.7%+43.3%4.0%
AGENAgenus Inc.Mar 2026$213K -80.6%—0.1%
SPROSpero Therapeutics, Inc.Mar 2026$153K +0.0%-75.3%0.3%
ENTXEntera Bio Ltd.Mar 2026$96K +1500.0%—0.7%
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$83K -73.0%-1.1%0.1%
HURATuHURA Biosciences, Inc.Mar 2026$33.77K —+594.4%0.1%
MCRBSeres Therapeutics, Inc.Mar 2026$31K -0.0%-85.6%0.0%
IRDOpus Genetics, Inc.Mar 2026$0 ——0.0%
ANIXAnixa Biosciences, Inc.Apr 2026$0 ——0.0%
Peer median (excluding ENTX) $83K-19.8%+21.1%0.1%

Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents24.89M12.31M11.02M8.66M7.11M
Short-term Investments00000
Net Receivables183K246K0126K219K
Inventory00000
Other Current Assets254K294K238K186K(219K)
Total Current Assets25.33M12.85M11.26M8.97M7.11M
Property, Plant & Equipment (Net)395K229K488K332K134K
Goodwill00000
Intangible Assets00000
Long-term Investments00080K90K
Tax Assets217K43K14K00
Other Non-current Assets46K6K6K6K(90K)
Total Non-current Assets658K278K508K418K134K
Total Assets25.99M13.13M11.77M9.39M15.99M
Account Payables166K17K83K132K448K
Short-term Debt00000
Tax Payables134K0000
Deferred Revenue15K0000
Other Current Liabilities455K300K500K339K432K
Total Current Liabilities3.16M1.34M1.09M1.18M2.2M
Long-term Debt0000260K
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities138K32K32K32K429K
Total Non-current Liabilities261K32K288K134K689K
Total Liabilities3.42M1.37M1.38M1.31M2.89M
Common Stock001K1K1K
Retained Earnings(82.43M)(95.5M)(104.39M)(113.93M)(125.37M)
Accumulated OCI41K41K41K41K41K
Other Stockholders Equity00000
Minority Interest00000
Total Equity22.57M11.75M10.39M8.08M13.1M
Total Debt302K91K390K272K490K
Net Debt(24.59M)(12.22M)(10.63M)(8.39M)(6.62M)

Entera Bio Ltd.

NASDAQ:ENTX

Intrinsic Alpha fair value

Locked

Current Price

$3.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.